Results 101 to 110 of about 21,299 (206)

Temporal Drivers of Opioid‐Related ED Visits: An Ensemble Machine Learning Study With Consensus‐Based Feature Attribution

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Identification of modifiable risk factors for prescription opioid use disorder (OUD)‐related emergency department (ED) visits (ICD‐10 F11.xx) is a clinical priority; however, most published models remain cross‐sectional and lack pharmacogenomic (PGx) enrichment or dual‐method feature confirmation. Using Virginia All‐Payer Claims Database (APCD)
R. Jerome Dixon, Elvin T. Price
wiley   +1 more source

A Serverless Pharmacogenomic Risk Dashboard: Translating Ensemble Models and Model‐Based Scenario Rules to Clinical Decision Support

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The “last mile” problem in healthcare AI—translating high‐performance models into accessible, privacy‐preserving point‐of‐care tools—remains unsolved for pharmacogenomic (PGx) risk assessment. No existing platform integrates opioid and polypharmacy risk scoring, model‐based scenario analysis, and CPIC‐based PGx patient cards within a single ...
R. Jerome Dixon, Elvin T. Price
wiley   +1 more source

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence

Pharmacogenomics and Personalized Medicine, 2020
Megan N Gower,1 Lindsay R Ratner,1 Alexis K Williams,1 Joseph S Rossi,2 George A Stouffer,2,3 Craig R Lee1,3 1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA; 2Division of Cardiology, UNC ...
Gower MN, Ratner LR, Williams AK, Rossi JS, Stouffer GA, Lee CR   +5 more
doaj  

Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects

Pharmacogenomics and Personalized Medicine, 2019
Margarita N Dorofeeva,1 Evgenia V Shikh,2 Zhanna M Sizova,1 Alisa V Tarasenko,3 Natalia P Denisenko,4,5 Valeriy V Smirnov,6,7 Kristina A Ryzhikova,4 Zhannet A Sozaeva,4 Elena A Grishina,4 Dmitriy A Sychev5 1Department of Social Expertise, Urgent and ...
Dorofeeva MN, Shikh EV, Sizova ZM, Tarasenko AV, Denisenko NP, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA, Sychev DA   +9 more
doaj  

CYP2C19 Gene [PDF]

, 2020
openaire   +1 more source

Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel

Balkan Journal of Medical Genetics
Clopidogrel, is a standard treatment in the prevention of major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD).
Nestorovska KA, Naumovska Z, Staninova Stojovska M, Sterjev Z, Dimovski A, Suturkova Lj   +5 more
doaj   +1 more source

CYP2C19 Inhibitor [PDF]

, 2020
openaire   +1 more source

CYP2C19 Inducer [PDF]

, 2020
openaire   +1 more source

CYP2C19*2 polymorphism and clopidogrel resistance [PDF]

Archivos de cardiolog�a de M�xico (English ed. Internet), 2021
Beuy, Joob, Viroj, Wiwanitkit
openaire   +2 more sources

CYP2C19 Substrate [PDF]

, 2020
openaire   +1 more source